Hyderabad-based Natco Pharma recently received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic semaglutide injection in India.
About Semaglutide:
It belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs.
It mimics the GLP-1 hormone, released in the gut in response to eating.
One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose).
For that reason, semaglutide is used for the following:
to control blood sugar levels in certain patients with type 2 diabetes (a condition in which blood sugar is too high because the body does not make or use insulin normally).
to reduce the risk of a heart attack, stroke, or death in adults with type 2 diabetes, heart and blood vessel disease, also in adults who are obese or overweight.
to reduce the risk of worsening of kidney disease and death in certain adults with type 2 diabetes and kidney disease
to assist with weight loss in certain people who are obese or overweight and have weight-related medical problems.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
